Japan’s home diagnostic testing market is expected to grow from approximately $448 million in 2025 to approximately $741 million by 2035. The market is projected to expand at a CAGR of approximately 5.2%, with demand from older adults expected to drive growth.
Japan’s home diagnostic testing market was valued at approximately $448.2 million in 2025 and is projected to expand at a CAGR of 5.2% from 2026 to 2035. The market is expected to reach approximately $744.1 million by 2035, with the increase in chronic diseases and the aging population, greater convenience of at-home testing, and integration with AI and telemedicine cited as growth drivers.
In terms of market structure, older adults have historically accounted for approximately 60% of sales and are expected to record the highest growth going forward. Demand is strong for self-testing for conditions requiring ongoing management, such as diabetes and cardiovascular disease, while demand is also increasing for minimally invasive samples, including urine and saliva.
Infectious disease testing has historically accounted for approximately 40% of total sales, with strong demand for tests for influenza and COVID-19. Urine testing has historically held the largest share of sales, while saliva testing is becoming increasingly important because of its lower psychological burden. Pregnancy and ovulation tests are also becoming more widely used for at-home testing.
In 2024, corporate activity related to at-home testing intensified. MEDIROM Healthcare Technologies acquired a 70% stake in Japan Gene Medicine Corporation to expand its wellness and preventive healthcare businesses, while Hitachi High-Tech and Gencurix entered into a strategic partnership covering molecular diagnostic services in the cancer field. These developments can be viewed as broader trends indicating the expanding application of at-home testing solutions.